中国人胃和胃食管结合部腺癌中 HER2 的表达及相关临床病理特征。
HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population.
机构信息
Department of Pathology, Cancer Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
出版信息
Diagn Pathol. 2013 May 9;8:76. doi: 10.1186/1746-1596-8-76.
BACKGROUND
With varied immunohistochemistry scoring criteria and patient cohorts, HER2-positivity rates in gastric cancer (GC) and gastroesophageal junction (GEJ) adenocarcinoma have been reported with a wide range. Recently standardized scoring criteria for GC and GEJ cancer has been established and recommended. In this study, the frequency of HER2 expression and the relationship between HER2 expression and clinicopathological features were examined in a large cohort of Chinese GC and GEJ cancer patients.
METHODS
A total of 1463 patients, including 929 primary GCs and 534 primary GEJ adenocarcinomas, was retrospectively analyzed for HER2 overexpression by immunohistochemistry (IHC). Fluorescence in situ hybridization (FISH) analysis was used in 308 GCs and GEJ adenocarcinoma cases to assess HER2 gene amplification.
RESULTS
HER2 overexpression (3+) was detected in 9.8% of carcinomas and more frequently observed in GEJ cancer cases, in the intestinal type, and in the well or moderately differentiated type (P=0.003, 0.000, and 0.000, respectively). HER2 equivocal (2+) was detected in 14.4% of cases. As for the 308 cases analyzed by FISH, 39 (of 40, 97.5%) IHC 3+ cases, 11 (of 38, 28.9%) IHC 2+ cases, and 3 (of 230, 1.3%) IHC 1+/0 cases showed HER2 gene amplification. A high concordance rate (98.5%) between IHC and FISH was demonstrated.
CONCLUSIONS
Approximately 10% of Chinese patients with primary GC and GEJ adenocarcinoma were HER2-positive on IHC. HER2 overexpression was associated with GEJ site, intestinal cancer subtype, and well or moderately differentiated carcinomas.
VIRTUAL SLIDES
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1935951199941072.
背景
由于免疫组织化学评分标准和患者队列的不同，胃癌（GC）和胃食管交界处（GEJ）腺癌的 HER2 阳性率报告差异很大。最近，GC 和 GEJ 癌症的标准化评分标准已经建立并得到推荐。在这项研究中，我们在一大群中国 GC 和 GEJ 癌症患者中检查了 HER2 表达的频率以及 HER2 表达与临床病理特征之间的关系。
方法
共回顾性分析了 1463 例患者，包括 929 例原发性 GC 和 534 例原发性 GEJ 腺癌，通过免疫组织化学（IHC）检测 HER2 过表达。荧光原位杂交（FISH）分析用于 308 例 GC 和 GEJ 腺癌病例，以评估 HER2 基因扩增。
结果
在 9.8%的癌组织中检测到 HER2 过表达（3+），并且在 GEJ 癌、肠型和中高分化型中更常见（P=0.003、0.000 和 0.000）。HER2 不确定（2+）的比例为 14.4%。在通过 FISH 分析的 308 例病例中，IHC 3+的 39 例（40 例，97.5%）、IHC 2+的 11 例（38 例，28.9%）和 IHC 1+/0 的 3 例（230 例，1.3%）显示 HER2 基因扩增。IHC 和 FISH 之间具有高一致性（98.5%）。
结论
中国约 10%的原发性 GC 和 GEJ 腺癌患者的 IHC 呈 HER2 阳性。HER2 过表达与 GEJ 部位、肠型癌症亚型以及中高分化癌有关。
Zotero 插件